Table 3.
First trimester zidovudine exposure and risk of malformations: MAX and posterior Bayesian analysis results
| Risk in full sample: zidovudine in Trimester 1 (N=823) | Risk in full sample: no zidovudine in Trimester 1 (N=1,998) | Risk in matched sample: zidovudine in Trimester 1 (N=735) | Risk in matched sample: no zidovudine in Trimester 1 (N=735) | Posterior estimates: Bayesian analysis results | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | OR | 95% credible interval | ||
|
|
|||||||||||
| Overall malformation | 38 | 4.6 | 79 | 4.0 | 34 | 4.6 | 36 | 4.9 | 1.11 | 0.80 | 1.55 |
| Cardiac malformation | 12 | 1.5 | 29 | 1.5 | 11 | 1.5 | 12 | 1.6 | 1.30 | 0.63 | 2.71 |
| Male genital malformation | 0 | 0.0 | <111 | -- | 0 | 0.0 | <111 | -- | N/A | -- | -- |
Abbreviations: MAX, Medicaid Analytic eXtract; OR, odds ratio
1
Cell sizes of 10 or less have been suppressed in accordance with Centers for Medicare and Medicaid Services cell size suppression policy.